Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types,
accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E …

Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation,
differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase …

Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large
multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid …

FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid
target in FGFR-deregulated tumors. Here, we examine the preclinical profile of futibatinib …

Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast
growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer. However …

Resistance becomes major clinical issue in cancer treatment, which strongly limits patients
to benefit from oncotherapy. Growing evidences have been indicative of the critical role of …

With the genetic portraits of all major human malignancies now available, we next face the
challenge of characterizing the function of mutated genes, their downstream targets …

SARS-CoV-2 sequences can be reverse-transcribed and integrated into the genomes of
virus-infected cells by a LINE1-mediated retrotransposition mechanism. Whole-genome …

ABSTRACT Fibroblast Growth Factor (FGF) ligands and their receptors are crucial factors
driving chemoresistance in several malignancies, challenging the efficacy of currently …

Ras p21 protein activator 1 (RASA1) is a regulator of Ras GDP and GTP and is involved in
numerous physiological processes such as angiogenesis, cell proliferation, and apoptosis …